TherapeuticsMD (TXMD) EBITDA Margin (2011 - 2026)

TherapeuticsMD (TXMD) has reported EBITDA Margin for 16 consecutive years, with 93.9% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 2090.0% year-over-year to 93.9%; the trailing twelve-month figure through Jun 2026 stood at 120.89% (up 2612.0% YoY), and the FY2025 full-year result was 145.27%, up 20181.0% from the prior year.
• EBITDA Margin improved to 93.9% in Q2 2026 per TXMD's latest filing, from 99.86% in the prior quarter.
• Across five years, EBITDA Margin topped out at 70.94% in Q4 2022 and bottomed at 4211.78% in Q2 2022.
• Historically, EBITDA Margin has averaged 1018.59% across 5 years, with a median of 313.48% in 2025.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin tumbled 405884 bps in 2022, then surged 364611 bps in 2023.
• Over 5 years, EBITDA Margin stood at 70.94% in 2022, then sank by 524 bps to 301.0% in 2023, then soared by 68 bps to 97.75% in 2024, then sank by 78 bps to 173.8% in 2025, then jumped by 46 bps to 93.9% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 93.9%, 99.86%, and 173.8% for Q2 2026, Q1 2026, and Q4 2025 respectively.